Next Article in Journal
Identification of Novel PI3Kδ Selective Inhibitors by SVM-Based Multistage Virtual Screening and Molecular Dynamics Simulations
Previous Article in Journal
miRNAs and Novel Food Compounds Related to the Browning Process
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 20
Issue 23
10.3390/ijms20235999
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors

by
Hui Li
1,2,3,†,
Jinglin Zhang
1,2,3,†,
Joanna Hung Man Tong
1,3,
Anthony Wing Hung Chan
1,3,
Jun Yu
2,4,
Wei Kang
1,2,3,* and
Ka Fai To
1,2,3,*
1
Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China
2
Institute of Digestive Disease, State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China
3
Li Ka Shing Institute of Health Science, Sir Y.K. Pao Cancer Center, The Chinese University of Hong Kong, Hong Kong, China
4
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Int. J. Mol. Sci. 2019, 20(23), 5999; https://doi.org/10.3390/ijms20235999
Submission received: 29 October 2019 / Revised: 23 November 2019 / Accepted: 25 November 2019 / Published: 28 November 2019
(This article belongs to the Section Molecular Oncology)
Browse Figures
Versions Notes

Abstract

:
Colorectal cancer (CRC) is a kind of solid tumor and the third most common cancer type in the world. It is a heterogeneous disease characterized by genetic and epigenetic aberrations. The TP53 mutation is the key step driving the transition from adenoma to adenocarcinoma. The functional roles of TP53 mutation in tumor development have been comprehensively investigated. In CRC, TP53 mutation was associated with poor prognosis and chemoresistance. A gain of function (GOF) of p53 mutants promotes cell proliferation, migration and invasion through multiple mechanisms. Restoring wild type p53 function, depleting p53 mutants, or intervention by targeting the oncogenic downstreams provides potential therapeutic strategies. In this review, we comprehensively summarize the GOF of p53 mutants in CRC progression as well as in some other solid tumors, and discuss the current strategies targeting p53 mutants in malignancies.

1. Introduction

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer deaths worldwide [1]. CRC is a heterogeneous disorder that possesses a variety of genomic and epigenetic aberrations. The loss of genomic stability drives the development of CRC by facilitating the acquisition of multiple tumor-associated mutations. These mutations control the capability of inhibiting tumor-suppressive genes and activating oncogenes, which have long been considered crucial events in CRC carcinogenesis. The earliest genetic event in colorectal tumorigenesis is activation of WNT signaling through the genetic disruption of APC. The APC somatic mutations rates increasingly with the disease progression, forming dysplastic aberrant crypt foci to adenomas and to sporadic carcinoma, with 5%, 30%–70% and 72%, respectively. It suggests that functional loss of APC is the initiating event in CRC [2,3,4]. The p53 pathway can be inhibited by mutation of TP53. This is the second key genetic step in CRC, which coincides with the transition from large adenomas into adenocarcinoma. TP53 mutation occurs in 40%–50% of sporadic CRC [5]. The status of TP53 mutation is correlated with progression and poor outcome of CRC. In recent years, some small molecule compounds have been intensively investigated for reactivation and restoration of p53 via different mechanisms. Some promising compounds are being tested in clinical trials and may be approved and employed for the treatment of CRC patients in the near future.

2. The Introduction of TP53 and Tumor Suppressive Role of p53

2.1. The Finding of TP53

In 1979, the p53 protein was first identified. Its discovery was a product of research into viral etiology and the immunology of cancer. In 1979, two groups simultaneously reported similar results about the existence of a protein of around 55 kDa that bound to large T antigen in various types of cancerous cells [6,7]. The p53 protein was named from its protein weighing 53 KDa. The protein was actually regarded as an oncogene at that time, as many tumors produce abundant levels of this protein—a phenomenon that was not observed in normal tissue, and ectopic expression of newly cloned TP53 cDNA was shown to cooperate with oncogenic Ras to transform primary cells in culture [8,9,10]. However, it was soon recognized that p53 overexpression could transform cells and promote in vivo tumor growth. This discrepant finding can be attributed to the use of different mutated versions of p53, which originally derived from tumor cells [11,12]. In 1989, the first murine wild type TP53 cDNA was cloned and it was found that there was an absence of oncogenic activity [13]. The reports of the anti-proliferative property of wild type p53 and the demonstration of inactivating mutations in colorectal cancer eventually changed the recognition of TP53 to a tumor suppressor gene [14,15].

2.2. The Functional Role of Wild Type p53

The tumor suppressor gene TP53 is located on the short arm of chromosome 17 (17p13.1), and p53 is a modular protein with 393 amino acids harboring four functional domains. The N-terminal domain or transactivation domain (NTD or TA) possesses an acidic N-terminal transactivation domain (1–42) and a proline-rich domain (40–92). The proline-rich domain contains a second transactivation domain, which is essential for binding to transcription factors and regulators of p53 activity [16]. The centrally located sequence-specific DNA-binding domain (DBD) (101–306) allows the binding to DNA [17]. Followed by an oligomerization domain (307–305), which contains a nuclear export signal involved in the tetramerization of p53, and a basic C-terminal regulatory domain (356–393) includes three nuclear localization signals, which are relevant for the post-translational modifications [18,19]. p53 is a short-lived protein with a half-life of 6–20 minutes. The amount of p53 protein in cells is determined mainly by the rate at which it is degraded. In normal cells, the ubiquitin-mediated proteolysis is the main process for p53 degradation, the MDM2 (murine/human double minute 2) protein is one of the enzymes involved in labelling p53 with ubiquitin. This process is a feedback loop. Once activated, p53 upregulates its negative regulator MDM2. Then, MDM2 binds with p53 to regulate the ubiquitination of p53, which leads to its degradation and helps to maintain low expression of wild type p53 [20]. In the presence of cellular stress, the p53 network is activated. One of the effects of p53 activation is to regulate the cell-division cycle. The cyclin-dependent kinases (CDKs) and cyclins are key regulators which control the cell cycle process. p21 (WAF1) is one member of the CDK inhibitors which take part in the inhibition of transition from G1 to S phase and G2 to M phase. p21 is a downstream target gene of p53 and it has been shown to take part in the p53-induced cell cycle arrest, along with other p53 target genes including retinoblastoma protein (Rb), GADD45, 14-3-3σ, and cRRIMA-1MET [21]. The Bax protein is one member of the Bcl-2 protein family, which can be activated by p53 to induce apoptosis [22]. Besides, Noxa and PUMA were found to be directly activated by p53 and their high expression can induce apoptosis [23]. p53 induces the expression of some DRs (death receptors), such as Fas, DR5 and PIDD, which form death-inducing signally complex with caspase-8 [24]. p53 expression may also induce death by direct stimulating mitochondria to produce an excess of highly toxic reactive oxygen species. Cellular senescence can be activated by p53. p16 and PML have been reported to take part in this activity, as well as p21 [25]. p53 also plays an important role in genome integrity, and in the regulation of cell metabolism [26,27]. Moreover, p53 promotes GLS2 transcription, leads to glutamine metabolism and reduces Reactive Oxygen Species (ROS) production [28]. p53 regulates nucleic acid biosynthesis. It can promote lipid biosynthesis by inhibiting SREBP-1 and G6PD, or inhibits lipogenesis by activating SIRT1, Aromatase, Acad11, Lipin1, MCD, and DHRS3 [29,30]. p53 plays a role in inhibiting cell migration and invasion through blocking filopodia formation, fibronectin formation, cellular expansion and polarization, which is mediated by suppressing Rac, RhoA, and Cdc42 expression [31]. p53 exerts a suppressive role in angiogenesis by activating the expression of angiogenesis inhibitor TSP-1 as well [32,33].

3. TP53 Mutation in CRC and Other Solid Tumors

3.1. TP53 Mutational Spectrum in CRC

TP53 is among the five most frequently mutated genes in human cancer. The frequency of TP53 mutations is highly variable between different cancer types. The TP53 alteration data can be accessed from the IARC TP53 Database (http://www-p53.iarc.fr/) [34], which compiles all TP53 mutations reported in human cancers, updated to August 2018. In this database, the TP53 mutation frequency ranges from 14.4% in endocrine gland tumor to 43.28% in CRC. More than 96% of TP53 mutations are mainly located in exons 5, 6, 7, 8 and 4, and 93% of TP53 mutations cluster are between codon 100 and 300, which is regarded as the DNA-binding domain. Among them, codon 248, 273, 175, 245, 282 and 249 are the top six mutated codons, with 6.79%, 6.55%, 4.8%, 3.12%, 2.59% and 2.59% mutational rates, respectively. The transversion of GC > AT at CpG is the highest in all the transversion types. TP53 mutations are associated with lymphatic invasion in proximal CRC and show a significant correlation with both lymphatic and vascular invasion in distal CRC. CRC patients with mutant p53 appear more chemo-resistance and have a poorer prognosis than those with wild-type p53.

3.2. The Mechanisms of p53 Mutants with Gain of Fucntion (GOF)

There are two major genetic mechanisms about the p53 locus alteration. One is the deletion of TP53 gene, which is mainly induced by transacting mutation, deletion, insertion or frameshift substitution. Another is missense mutations, which has been found to attenuate p53 function. The outcomes of p53 mutants are loss of tumor suppressor activity or GOF to support tumor progression. Among cancers with TP53 missense mutations, about 60% show concomitant deletion of the other allele. This deletion is termed as loss of heterozygosity (LOH) which results in abrogate the tumor suppressor function of the affected TP53 allele [35]. Around 40% of cases with p53 mutants keep a wild-type TP53 allele. In these cases, it has been shown that the dominant negative effects (DNE) of p53 mutants play a repressing role on the wild type p53 protein (Figure 1).
The p53 mutants retain the ability to form a protein–tetramer complex. This kind of complex is called a heterodimer complex as it is a mixture of mutated and wild type proteins, which suppress p53 wild-type function by inhibiting its normal DNA binding activity [36]. While losing tumor suppressive function, p53 mutants can gain new oncogenic functions to promoting cell transformation, tumor progression, metastasis, and chemo-resistance [37]. The mechanisms of p53 mutant GOF have been well studied. Plenty of studies have examined the binding affinity of different p53 mutants to known transcription factors (TFs). In colon cancer, the mutant R248W binds to Mre11, while R273H binds to NF-Y, Mre11, or YAP1 in cell lines HT29, SW620, SW480, respectively [38,39]. The p53 mutants R175H, R248W, R273H, Y220C, E258V, R110P and R282W have been shown to interact with p63 and p73, which prevents their binding to targeted promoters and inhibits target gene expression [37]. A common set of TFs such as ETS1/2, E2F1, NF-Kb and SMADs may be bound by different p53 mutants and activate their target genes to impart GOF activities. Likewise, p53 mutants promote the expression of c-Myc and Bcl-XL, which enhances cell growth [40]. Meanwhile, the binding of p53 mutants with p63 and p73 subverts their target gene activation, which promotes cell motility, invasion and metastasis [41,42]. In addition, a single p53 mutant variant may interact with multiple TFs, which activates a number of target genes. Collectively, the interaction between p53 mutants with other TFs has been recognized as main mechanism to mediate and amplify the GOF of p53 mutants. Also, p53 mutants increase chromatin accessibility and enhance gene expression within spans of accessible chromatin (Figure 2).

3.3. Oncogenic Roles of p53 Mutants with GOF

The concept that p53 mutants may exert GOF activity was previously demonstrated by introducing the p53 mutant protein into p53 null cells, which promoted cell growth and tumorigenic potential [43,44,45]. Since this discovery, studies have shown many GOFs in numerous cell lines with a variety of p53 mutations. These GOF activities include promoting tumorigenesis, activating tumor invasion and migration, and driving chemo-resistance. Recent findings are summarized in Table 1.

3.3.1. Enhancing Cell Proliferation and Colony Formation

p53 mutants play an important role in sustaining the proliferation and evasion of growth suppression in tumorigenesis. In glioblastoma, mutant p53 R273H forms a complex with CBP and NFY, then activates the oncogenes c-Myc and Bcl-XL, thus promoting cancer cell proliferation, colony formation, invasion and survival [40]. The p53 mutants R280K and R282W were found to suppress KLF17, which is a negative regulator for breast cancer metastasis. The suppression of KLF17 by p53 mutant enhanced cell growth, migration and invasion [46]. A novel mutant p53 R273H/miR-27a/EGFR pathway is discovered that play important roles in facilitating cancer cell proliferation, colony formation and tumorigenesis [47]. In lung cancer, several p53 mutants (R175H, R273H, R273C, D281G and R267P) are shown to increase Axl expression, leading to cell growth and tumorigenesis [48]. p53 mutants also promote tumor growth in a xenograft mouse model [49]. p53 mutants are identified along with their binding partner, ETS2, to regulate the expression of numerous nucleotide metabolism genes (NMG), which sustain proliferation and invasion [50]. Enhanced proliferation is also seen upon the activation of the REG-γ proteasome pathway by p53 mutants [51,52].
Multiple factors are involved in the p53 mutants mediated colony formation. p53 mutant R273H attenuates the activation of NRF2, directly resulting in functional loss of NRF2 in ROS detoxification. In cells expressing p53 mutant, the high level of ROS fails to induce growth arrest but promotes cancer cell growth and colony formation [53]. TopBP1 is found to promote p53 mutants and p300 recruitment to NF-Y target gene promoters, thus inhibiting the transcriptional activities of p63/p73. TopBP1 is believed to mediate cancer cell growth and chemotherapy resistance caused by p53 mutants [54]. HSF1 can also affect clonogenic growth in a p53 context dependent manner. In p53 mutant existence, HSF1 significantly increased cells clonogenic growth [55]. p53 mutants increase GRO1 expression, which promotes cancer cell growth and colony formation. While GRO1 knockdown inhibits cell growth and abrogates p53 mutant GOF in SW480 cells [56].

3.3.2. Promoting Migration, Invasion and Metastasis

Cells expressing p53 mutants R175H, R273H and D281G show increased migration, with elevated expression of CXCL5, CXCL8 and CLCX12. The inhibition of CXCL5 by RNAi suppressed cell migration [57]. In breast cancer, Pin1 enhances tumorigenesis in a p53 mutant knocking mouse model and it amplifies p53 mutant pro-migration function in vitro. Patients with high expression of Pin1 with p53 mutants show the worst overall survival [58]. The target genes regulated by p53 mutants include c-Myc, Bcl-XL, KLF17, Axl, Sharp1, Cyclin G2 and other oncogenes regulated by let-7i [40,41,46,48,59].
The role of p53 mutant GOF in invasion and metastasis is one of the most well-studied points. The p53 mutant R175H and R273H are found to promote invasive behavior in cancer and normal cells in vitro and in vivo. This is mediated by AKT signaling activation driven by p53 mutants. RCP-dependent recycling of integrin and EGFR are involved in this process [60]. Alternatively, p53 mutants promote cancer invasion through inhibition of Dicer function by direct downregulation of the TAp63 dependent transcriptional activation of Dicer or independent manner [61]. The p53 mutants are also found to enhance MET recycling to promote cell scattering and invasion in TAp63 dependent and independent mechanisms [62]. p53 mutants could interact with and inhibit TAp63 to regulate genes that increase invasion through TGF-β signaling [41]. p53 mutants were observed to promote cancer cell invasion by attenuating and cooperating with the TGF-β pathway by targeting Smad3 [42]. miRNA let-7i is found to be a direct target of p53 mutant/p63 complex, which affects cancer cell invasion; migration by regulating a network of oncogenes including E2F5, LIN28B; and NRAS [59].
Various other TFs play roles in p53 mutant-driven invasion and metastasis. It has been shown that p53 mutants enhance pancreatic cancer cell metastasis by modulating p73 and through an interaction with NF-Y. p53 mutants induce PDGFR-β expression through inhibition of p73/NF-Y complex. Blocking of PDGFR-β prevents cancer cell invasion and metastasis formation both in vitro and in vivo [63]. In glioblastoma, a PTEN-dependent p53 mutant/CBP/NF-Y complex transcriptionally activates the oncogenes c-Myc and Bcl-XL, which results in enhanced cell proliferation, colony formation and invasion [40]. Through interacting with SREBPs, p53 mutants regulate the mevalonate pathway, leading to increased proliferation, invasion and metastasis [64]. In breast cancer patients, the high expression of genes in mevalonate pathway is associated with particularly poor survival. EGR1 is another TF regulated by p53 mutants, which activates Myo10 via MAPK/ERK signaling. Increased Myo10 promotes breast cancer invasion and metastasis [65]. Other genes directly regulated by p53 mutant, such as KLF17 and REG-γ, also participate in breast and endometrial cancer cell invasion, respectively [46,51].
In intestinal tumors, a loss of wild-type p53 alone might facilitate the invasion of benign tumors, although it is insufficient to drive the malignant process [66]. A previous study provides evidence in an APCΔ716 mouse model suggesting the nuclear enrichment of mutant p53R270H leads to tumor gland formation. This drives malignant progression and enhances the acquired invasiveness. Additionally, the mutant p53R270H upregulates a subset of genes associated with the activation of inflammatory and innate immune pathways. By that means, nuclear accumulation of p53R270H not only increases stemness in intestinal tumor cells by activating NF-κB pathway and Wnt signaling, but also remodels the microenvironment to accommodate the invasive properties of the tumor cells [67]. Cooperation of p53 mutants with other driver mutations and oncogenic pathways plays significant role during the multistep CRC tumorigenesis; thus, targeting p53 mutants might serve as an ideal strategy to inhibit CRC progression.

3.3.3. Inducing Angiogenesis

p53 mutants play an active role in promoting angiogenesis in vivo. The xenografts with p53 mutant expression demonstrate increased number of vessels compared with wild type p53 expressing tumors. This stimulation is depending on increased ROS level, which leads to upregulation of HIF1/VEGF pathway [68]. A significant correlation between high p53 mutant expression and VEGF is also found in breast cancers and gastrointestinal cancers [69,70]. The transcriptional axis of p53 mutants, E2F1 and ID4 are found to serve as a new molecular mechanism in promoting tumor angiogenesis. The complex of p53 mutants and E2F1 positively controls ID4 expression. The abundant ID4 activates pro-angiogenic factor IL8 and GROα, which supports the promotion of angiogenic potential of p53 mutants [71].

3.3.4. Inducing Chromatin Remodeling

In breast cancer, Pfister et al. discovered that VEGFR2 is a p53 mutant transcriptional target [72]. The binding of p53 mutants on the promoter region of VEGFR2 makes it open to benefit the binding of p53 mutant with the chromatin remodeling complex SWI/SNF. The SWI/SNF complex plays a an important role in maintaining VEGFR2 promoter remodeling. The absence of SWI/SNF leads to increased nucleosome occupancy, which decreases the binding of p53 mutants on VEGFR2 promoter and suppresses VEGFR2 expression [72].
p53 mutant was found to be involved in the transcription of the MLL1 and MLL2 histone methyltransferases and the MOZ histone acetyltransferase. This results in global changes in histone modifications, which enhances the activities of p53 mutant GOF. MLL1 and MLL2 are members of the SET family of histone methyltransferase enzymes. They act as parts of large complexes to regulate gene expression by attaching methyl groups to a H3K4 protein. The H3K4 methylation promotes expression of the gene packaged around the histones. The binding of p53 mutant with MLL1 and MLL2 leading to genome-wide histone methylation, which finally enhances cancer cell growth in vitro. The p53 mutant activates the transcription of gene MOZ, which encodes an enzyme that plays a role in shifting the acetyl group to H3K9. The level of H3K9 acetylation depends on p53 mutant expression, which confirmed the idea that p53 mutant affects histone modification. These results suggest new possibilities for cancer therapy by targeting chromatin modification for cancers driven by p53 mutants. For example, knocking down MLL1 markedly decreased tumor cell growth, and pharmacological inhibition of the MLL1 methyltransferase complex inhibited proliferation of cancer cells carrying p53 mutations, but did not affect those without p53 mutants [73].
p53 mutants might alter the enhancer landscape of tumor cells under the condition of chronic immune activation [74]. The enhancer specific p53 mutant binding events are correlated with RNAPII recruitment. p53 mutants modulate the TNF-α inducible activation of enhancers through regulation of RNAPII recruitment. In terms of the regulation of enhancer associated alterations, the patterns between p53 mutants and wild type were quite different. The expression of eRNA and mRNA of MMP9 and CCL2 is higher in tumors with TP53 mutation compared with tumors expressing wild-type p53. The findings support that the majority of p53 mutants are mis-localized to other transcriptional regions and interact with abnormal transcriptional regulators, while wild-type p53 is often recruited to typical sites. The p53 mutants regulate chromatin modification and this provides an opportunity of targeting chromatin modifying activities. JQ-1, a BRD4 inhibitor, can decrease the gene expression regulated by super enhancers [75]. BRD4 is a member of bromodomain and extraterminal domain (BET) proteins family. BET proteins recognize acetylated lysine residues on histone tails, recruit chromatin-modifying enzymes and transcription factors. BRD4 thereby plays key roles at the interface between chromatin modification and transcriptional regulation. The combination of JQ1 with arsenic sulfide synergistically activates wild type p53 and inhibits c-Myc in gastric and colon cancer cells and xenografts model [76,77].

4. Targeting p53 Mutants in Tumorigenicity

Much evidence shows that p53 mutants are stabilized in solid tumors and exert oncogenic GOF activities to promote cancer progression. The restoration of wild-type p53 function has been shown to be sufficient to induce rapid tumor regression in mice [82,83,84]. A larger number of studies have tried to exploit small molecule inhibitors targeting p53 mutants specifically. The main strategies include restoring the wild-type activity of p53 mutants, degrading p53 mutants, promoting synthetic lethality to p53 mutants, and quenching the related oncogenic p53 mutants’ downstream pathways (Figure 3).

4.1. Restoring the Function of Wild Type p53

4.1.1. Cysteine-Binding Compounds

CP-31398 is the first compound which protects native wild-type p53 from a denatured conformation and restores the wild-type function of some p53 mutants. It was identified through a structure-based screening. In various tumor cell lines, CP-31398 has been found to promote p21 and MDM2 expression [85]. p21 is upregulated in Saos-2 cells with ectopic expression of p53 mutants V173A and R249S, after treatment with CP-31398 [86]. CP-31398 inhibits tumor growth in CRC and melanoma xenograft mouse model [87]. CP-31398 can refold newly synthesized p53 mutants, but is unable to refold already misfolded mutant p53 proteins. This compound also promotes DNA damage and apoptosis in skin carcinoma cell line with p53 R273H mutant [88].
PRIMA-1 is the most well studied small molecule, and its methylated analog PRIMA-1MET (also known as APR-246) has been tested in phase I/II clinical trial. PRIMA-1 was originally identified from a screening of small molecules that inhibit cell proliferation in the Saos-2 cell line with ectopic expression of p53 mutants R273H and R175H, compared with control Saos-2 p53 null cells [89]. PRIMA-1 can restore DNA contact mutants, as well as structural p53 mutants. In the test, it has been found to rescue specific DNA binding to 13 of 14 p53 mutants, which leads to restoration of wild-type conformation and causes apoptosis in tumor cells [89]. PRIMA-1 and PRIMA-1MET are found to inhibit the proliferation of tumor cell lines with p53 mutations in vitro and quench the xenograft formation in animal models [90,91,92]. PRIMA-1 and PRIMA-1MET can activate wild type p53 target genes, including p21, MDM2, Noxa, Puma, BAX, GAD45 and miRNA-34a, which enhance cell death [90,91,92]. In addition, PRIMA-1MET was found to exert proapoptotic activity by conversion to more active molecule methylene quinuclidinone (MQ), which leads to an oxidative environment [93]. In phase I/IIa clinical trial, PRIMA-1MET have been confirmed to reduce bone marrow blasts in a patient with AML and reduce tumor size in a patient with non-Hodgkin lymphoma. A phase II clinical trial that evaluated the effects of a PRIMA-1MAT combination with carboplatin and pegylated doxorubicin is ongoing in high grade serous ovarian cancer patients with p53 mutants [94]. Phase Ib/II studies have begun, including a study of PRIMA-1MET in combination with cytosine analogue azacitidine in myelodysplastic syndrome and a study of PRIMA-1MET in combination with cisplatin and 5-FU in esophageal cancer [95,96]. Several other Cysteine-binding compounds have been also reported to restore wild type function of p53 mutants, including MIRA-1, STIMA-1, KSS-9, PK11007 and 3-Benzoylacrylic acid [97,98,99,100,101,102].

4.1.2. Zn2+-Chelating Compounds

Zinc is required for the proper folding of wild type p53, while the proper protein folding and function is prevented in p53 mutants lack of zinc binding ability. The addition of zinc to cells and tumors in a mice model with p53 mutations R175H and R273H has been found to restore p53 mutants’ DNA binding ability and prevent tumor progression [103]. Zinc metallochaperone-1 (ZMC-1), also known as NSC319726, has been identified to promote the binding of zinc with p53 mutants that restore the proper folding and transcriptional activity [104]. This was discovered from a screening with the NCI60 tumor cell line panel. The results showed that it is specifically toxic to cells with p53 R175H mutation. ZMC-1 repairs the wild-type-like conformation of p53 mutants and generates ROS to activate p53 downstream target genes including p21, PUMA and MDM2. Importantly, ZMC-1 induces greater toxicity to tumors in specific p53 R172H (equivalent to human R175H) mice and suppresses xenograft formation of cancer cells with p53 R175H mutant [104]. In addition, other zinc binding p53 mutations C176, C242, C238, H179 and M237 may been functionally reactivated by ZMC-1. COTI-2 is another Zn2+-chelating compound that has been reported to restore the folding and function of p53 mutants. It inhibits the PI3K–AKT pathway, induces cell death, and prevents xenograft growth in mice, carrying both p53 mutants and wild-type [105]. The exact mechanism is still not comprehensively understood. This kind of compound is now being tested in a phase I clinical trial in gynecological and head and neck cancers [106].

4.1.3. Peptides

Several peptides have been found to reactivate p53, which suppresses tumor growth in mouse xenograft models of breast, colon and ovarian cancer. A series of peptides were identified to convert p53 mutant conformation to the wild-type-like form, activate p53 targets, and induce apoptosis in tumor cells [107]. Reacp53 is found to block p53 mutant aggregation, and rescues p53 wild-type properties which induce cell cycle arrest and promote apoptosis in ovarian cancer cells [108].

4.1.4. Other Types of Compounds

The compounds PK083 and PK7088 can bind to p53 Y220C specific surface cavity, resulting in the refolding of the wild-type conformation [109,110]. P53R3 has been shown to restore the DNA-binding ability of p53 mutants 175H, R273H and M237. Further, it can increase the expression of p21, MDM2, BAX, PUMA, GADD45 and PIG3, and exert the p53 dependent anti-proliferation activity [111]. Another compound targeting p53 mutants is SCH529074. It can bind to p53 mutants’ core domain, increases p53 target genes’ expression, and inhibit p53 ubiquitination by MDM2 [112]. Chetomin, which binds to the heat shock protein 40 and promotes its interaction with p53 R175H mutant, suppresses growth of xenograft tumor in mice [113]. RETRA, which specifically disrupts the complex of p53 and p73, inhibits p53 R273H mutated xenograft growth [114].

4.2. Depleting Mutated p53 Proteins

In vitro experiments demonstrated that knocking down p53 mutants by siRNA suppresses cancer cell growth. An in vivo genetic ablation of p53 mutants induced by Tamoxifen effectively antagonized tumor invasiveness. It proves that GOF p53 mutants are feasible druggable targets in CRC [115]. Thus, small molecules that specifically deplete p53 mutants are promising for cancer therapy. 17AAG, an inhibitor of HSP90, has been reported to degrade p53 mutants R175H, R273H, L194F and R280K and inhibit the tumor cell growth, which carries p53 mutations [116]. Ganetespib, another HSP90 inhibitor, is currently being tested in a clinical trial of lung cancer and it has been shown to be over 50-fold more potent than 17AAG in depleting p53 mutants [49]. The histone deacetylase inhibitor SAHA degrades p53 mutants by inhibiting HDAC6, and the disrupted HDAC6-HSP90-p53 mutant axis can lead to mutant p53 ubiquitination [117]. The arsenic trioxide increases transcripts of Pirh2 and induces proteasomal dependent degradation of several p53 mutants, including R175H, R248W, H179Y/R282W and R273H [118,119]. Gambogic Acid, spautin-1, YK-3-237, NSC59984 and Disulfiram are also found to degrade p53 mutants [120,121,122,123,124,125].

4.3. Inducing Synthetic Lethality to p53 Mutants

Inducing synthetic lethality of p53 mutant in tumors is another strategy for therapy. UCN01, an inhibitor of protein kinase C and a potent blocker of G2/M checkpoint, has been shown to increase the irradiation cytotoxicity to CA46 cells with p53 R248Q and HT29 cells with p53 R273H [126]. The BI-2536 and PD0166285 also have been observed to lead synthetic lethality to p53 mutants through hindering G2/M transition. These two compounds can increase the cytotoxic effect of ionizing radiation in DLD-1 p53 S241F and HCT116 p53 R248W cell lines, but not in a cell line with wild-type p53 [127,128].

4.4. Targeting the Oncogenic Downstreams of p53 Mutants

In order to suppress the oncogenic property of p53 mutants, another effective way is to disrupt tumor-promoting signaling activated by mutant p53. The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase regulates prenylation/lipidation of proteins. Prenylation plays a role in cellular adhesion, migration, and proliferation signaling through facilitating attachment of target proteins to cell membranes. Statins play an important role in suppressing HMG-CoA reductase, and have been applied in patients with hypercholesterolemia disease. In breast cancer cells, p53 mutant binds to and activates SREBP, resulting in activation of prenylated proteins. Thus, statins inhibit breast tumor growth through suppressing p53 mutants and protein prenylation [64]. Moreover, the Rho GTPases’ prenylation promotes nuclear localization and activation of the YAP/TAZ. Statins suppress Rho GTPase prenylation and YAP/TAZ activation, thus preventing tumor development carrying p53 mutants [129].
The main compounds potentially targeting p53 mutant are listed in Table 2.

5. Conclusions and Future Directions

Although many studies have explored the mechanisms of p53 mutants with GOF, the mechanisms have not been fully elucidated. Thus, targeted therapy on p53 mutants has been regarded as one of the hardest medical issues. More importantly, CRC is a heterogeneous disease with high recurrence rates and it is hard to achieve a better therapeutic effect by solely targeting p53 mutants. We are glad to see that several clinical trials targeting p53 mutants get satisfied therapeutic effects or combinational administration of p53 mutant inhibitors with other small molecules which exert a synergetic effect on inhibiting tumor growth. However, several urgent issues have to be addressed in the coming studies. First, as a transcription factor, p53 mutants bind with novel transcriptional regions and it is imperative to perform ChIP-seq on different p53 mutants to reveal the specific or common downstream targets or pathways. Second, the involvement of p53 mutants in histone modification, especially the relationship with super enhancer, has gradually become a hot topic in research. Thus, integrative analysis of p53-mutant ChIP-seq with H3K4me3/H3K27ac ChIP-seq needs to be performed to reveal novel epigenetically regulated targets. Last, but not least, stratifying the primary CRC samples and cell lines based on the p53 related genetic and epigenetic background will be performed for the accurate administration of small molecules in the wet-lab research and clinical trials. With the increased knowledge of p53 mutants, more and more advanced intervention strategies will be developed in the precision medicine era.

Author Contributions

K.F.T. provided direction and instruction in preparing this manuscript. H.L. and J.Z. reviewed the literature and drafted this manuscript. J.H.M.T., A.W.H.C., J.Y. and W.K. reviewed the manuscript and made significant revisions on the drafts.

Funding

The current manuscript was supported by Research Grants Council of the Hong Kong Special Administrative Region, China [Project No.: CUHK 14100019, 14118518 (for GRF projects)], and CUHK Direct Grant for Research (2018.002) from The Chinese University of Hong Kong.

Acknowledgments

We acknowledge the technical support from Core Utilities of Cancer Genomics and Pathobiology of Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong.

Conflicts of Interest

The authors have no conflict of interest to declare.

References

  1. Bhandari, A.; Woodhouse, M.; Gupta, S. Colorectal cancer is a leading cause of cancer incidence and mortality among adults younger than 50 years in the USA: A SEER-based analysis with comparison to other young-onset cancers. J. Investig. Med. Off. Publ. Am. Fed. Clin. Res. 2017, 65, 311–315. [Google Scholar] [CrossRef] [PubMed]
  2. Otori, K.; Konishi, M.; Sugiyama, K.; Hasebe, T.; Shimoda, T.; Kikuchi-Yanoshita, R.; Mukai, K.; Fukushima, S.; Miyaki, M.; Esumi, H. Infrequent somatic mutation of the adenomatous polyposis coli gene in aberrant crypt foci of human colon tissue. Cancer 1998, 83, 896–900. [Google Scholar] [CrossRef]
  3. Miyaki, M.; Konishi, M.; Kikuchi-Yanoshita, R.; Enomoto, M.; Igari, T.; Tanaka, K.; Muraoka, M.; Takahashi, H.; Amada, Y.; Fukayama, M.; et al. Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors. Cancer Res. 1994, 54, 3011–3020. [Google Scholar] [PubMed]
  4. Cottrell, S.; Bicknell, D.; Kaklamanis, L.; Bodmer, W.F. Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas. Lancet 1992, 340, 626–630. [Google Scholar] [CrossRef]
  5. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487, 330–337. [Google Scholar] [CrossRef]
  6. Lane, D.P.; Crawford, L.V. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979, 278, 261–263. [Google Scholar] [CrossRef]
  7. Linzer, D.I.; Levine, A.J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979, 17, 43–52. [Google Scholar] [CrossRef]
  8. DeLeo, A.B.; Jay, G.; Appella, E.; Dubois, G.C.; Law, L.W.; Old, L.J. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc. Natl. Acad. Sci. USA 1979, 76, 2420–2424. [Google Scholar] [CrossRef]
  9. Rotter, V. p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells. Proc. Natl. Acad. Sci. USA 1983, 80, 2613–2617. [Google Scholar] [CrossRef]
  10. Eliyahu, D.; Raz, A.; Gruss, P.; Givol, D.; Oren, M. Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature 1984, 312, 646–649. [Google Scholar] [CrossRef]
  11. Weiss, B.; Nitschko, H.; Ghattas, I.; Wright, R.; Schlesinger, S. Evidence for specificity in the encapsidation of Sindbis virus RNAs. J. Virol. 1989, 63, 5310–5318. [Google Scholar] [PubMed]
  12. Hinds, P.W.; Finlay, C.A.; Quartin, R.S.; Baker, S.J.; Fearon, E.R.; Vogelstein, B.; Levine, A.J. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: A comparison of the "hot spot" mutant phenotypes. Cell Growth Differ. 1990, 1, 571–580. [Google Scholar] [PubMed]
  13. Finlay, C.A.; Hinds, P.W.; Levine, A.J. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989, 57, 1083–1093. [Google Scholar] [CrossRef]
  14. Baker, S.J.; Fearon, E.R.; Nigro, J.M.; Hamilton, S.R.; Preisinger, A.C.; Jessup, J.M.; vanTuinen, P.; Ledbetter, D.H.; Barker, D.F.; Nakamura, Y.; et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989, 244, 217–221. [Google Scholar] [CrossRef]
  15. Takahashi, T.; Nau, M.M.; Chiba, I.; Birrer, M.J.; Rosenberg, R.K.; Vinocour, M.; Levitt, M.; Pass, H.; Gazdar, A.F.; Minna, J.D. p53: A frequent target for genetic abnormalities in lung cancer. Science 1989, 246, 491–494. [Google Scholar] [CrossRef]
  16. Unger, T.; Nau, M.M.; Segal, S.; Minna, J.D. p53: A transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J. 1992, 11, 1383–1390. [Google Scholar] [CrossRef]
  17. Cho, Y.; Gorina, S.; Jeffrey, P.D.; Pavletich, N.P. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 1994, 265, 346–355. [Google Scholar] [CrossRef]
  18. Stommel, J.M.; Marchenko, N.D.; Jimenez, G.S.; Moll, U.M.; Hope, T.J.; Wahl, G.M. A leucine-rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by NES masking. Embo J. 1999, 18, 1660–1672. [Google Scholar] [CrossRef]
  19. Romer, L.; Klein, C.; Dehner, A.; Kessler, H.; Buchner, J. p53—A natural cancer killer: Structural insights and therapeutic concepts. Angew. Chem. Int. Ed. Engl. 2006, 45, 6440–6460. [Google Scholar] [CrossRef]
  20. Li, Q.; Lozano, G. Molecular pathways: Targeting Mdm2 and Mdm4 in cancer therapy. Clin. Cancer Res. 2013, 19, 34–41. [Google Scholar] [CrossRef]
  21. Li, X.L.; Zhou, J.; Chen, Z.R.; Chng, W.J. P53 mutations in colorectal cancer-molecular pathogenesis and pharmacological reactivation. World J. Gastroenterol. 2015, 21, 84–93. [Google Scholar] [CrossRef] [PubMed]
  22. Reed, J.C. Dysregulation of apoptosis in cancer. J. Clin. Oncol. 1999, 17, 2941–2953. [Google Scholar] [CrossRef] [PubMed]
  23. Oda, E.; Ohki, R.; Murasawa, H.; Nemoto, J.; Shibue, T.; Yamashita, T.; Tokino, T.; Taniguchi, T.; Tanaka, N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000, 288, 1053–1058. [Google Scholar] [CrossRef]
  24. Lin, Y.; Ma, W.; Benchimol, S. Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis. Nat. Genet. 2000, 26, 122–127. [Google Scholar] [CrossRef]
  25. Li, T.; Kon, N.; Jiang, L.; Tan, M.; Ludwig, T.; Zhao, Y.; Baer, R.; Gu, W. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 2012, 149, 1269–1283. [Google Scholar] [CrossRef] [PubMed]
  26. Kondoh, H.; Lleonart, M.E.; Gil, J.; Wang, J.; Degan, P.; Peters, G.; Martinez, D.; Carnero, A.; Beach, D. Glycolytic enzymes can modulate cellular life span. Cancer Res. 2005, 65, 177–185. [Google Scholar] [PubMed]
  27. Schwartzenberg-Bar-Yoseph, F.; Armoni, M.; Karnieli, E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res. 2004, 64, 2627–2633. [Google Scholar] [CrossRef]
  28. Suzuki, S.; Tanaka, T.; Poyurovsky, M.V.; Nagano, H.; Mayama, T.; Ohkubo, S.; Lokshin, M.; Hosokawa, H.; Nakayama, T.; Suzuki, Y.; et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc. Natl. Acad. Sci. USA 2010, 107, 7461–7466. [Google Scholar] [CrossRef]
  29. Jiang, P.; Du, W.; Wang, X.; Mancuso, A.; Gao, X.; Wu, M.; Yang, X. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat. Cell Biol. 2011, 13, 310–316. [Google Scholar] [CrossRef]
  30. Parrales, A.; Iwakuma, T. p53 as a Regulator of Lipid Metabolism in Cancer. Int. J. Mol. Sci. 2016, 17. [Google Scholar] [CrossRef]
  31. Ferraiuolo, M.; Verduci, L.; Blandino, G.; Strano, S. Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers. Int. J. Mol. Sci. 2017, 18. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Dameron, K.M.; Volpert, O.V.; Tainsky, M.A.; Bouck, N. The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. Cold Spring Harb. Symp. Quant. Biol. 1994, 59, 483–489. [Google Scholar] [CrossRef] [PubMed]
  33. Teodoro, J.G.; Parker, A.E.; Zhu, X.; Green, M.R. p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science 2006, 313, 968–971. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Bouaoun, L.; Sonkin, D.; Ardin, M.; Hollstein, M.; Byrnes, G.; Zavadil, J.; Olivier, M. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data. Hum. Mutat. 2016, 37, 865–876. [Google Scholar] [CrossRef] [PubMed]
  35. Wu, S.; Liu, W.; Zhou, L. MiR-590-3p regulates osteogenic differentiation of human mesenchymal stem cells by regulating APC gene. Biochem. Biophys. Res. Commun. 2016, 478, 1582–1587. [Google Scholar] [CrossRef] [PubMed]
  36. Willis, A.; Jung, E.J.; Wakefield, T.; Chen, X. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 2004, 23, 2330–2338. [Google Scholar] [CrossRef] [Green Version]
  37. Feng, Y.C.; Ji, W.L.; Yue, N.; Huang, Y.C.; Ma, X.M. The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance. Cancer Manag. Res. 2018, 10, 105–113. [Google Scholar] [CrossRef] [Green Version]
  38. Di Agostino, S.; Sorrentino, G.; Ingallina, E.; Valenti, F.; Ferraiuolo, M.; Bicciato, S.; Piazza, S.; Strano, S.; Del Sal, G.; Blandino, G. YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins. EMBO Rep. 2016, 17, 188–201. [Google Scholar] [CrossRef]
  39. Marin, M.C.; Jost, C.A.; Brooks, L.A.; Irwin, M.S.; O’Nions, J.; Tidy, J.A.; James, N.; McGregor, J.M.; Harwood, C.A.; Yulug, I.G.; et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet. 2000, 25, 47–54. [Google Scholar] [CrossRef]
  40. Huang, X.; Zhang, Y.; Tang, Y.; Butler, N.; Kim, J.; Guessous, F.; Schiff, D.; Mandell, J.; Abounader, R. A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy. Neoplasia 2013, 15, 952–965. [Google Scholar] [CrossRef] [Green Version]
  41. Adorno, M.; Cordenonsi, M.; Montagner, M.; Dupont, S.; Wong, C.; Hann, B.; Solari, A.; Bobisse, S.; Rondina, M.B.; Guzzardo, V.; et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 2009, 137, 87–98. [Google Scholar] [CrossRef] [PubMed]
  42. Ji, L.; Xu, J.; Liu, J.; Amjad, A.; Zhang, K.; Liu, Q.; Zhou, L.; Xiao, J.; Li, X. Mutant p53 promotes tumor cell malignancy by both positive and negative regulation of the transforming growth factor beta (TGF-beta) pathway. J. Biol. Chem. 2015, 290, 11729–11740. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Dittmer, D.; Pati, S.; Zambetti, G.; Chu, S.; Teresky, A.K.; Moore, M.; Finlay, C.; Levine, A.J. Gain of function mutations in p53. Nat. Genet. 1993, 4, 42–46. [Google Scholar] [CrossRef] [PubMed]
  44. Olive, K.P.; Tuveson, D.A.; Ruhe, Z.C.; Yin, B.; Willis, N.A.; Bronson, R.T.; Crowley, D.; Jacks, T. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004, 119, 847–860. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Lang, G.A.; Iwakuma, T.; Suh, Y.A.; Liu, G.; Rao, V.A.; Parant, J.M.; Valentin-Vega, Y.A.; Terzian, T.; Caldwell, L.C.; Strong, L.C.; et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004, 119, 861–872. [Google Scholar] [CrossRef] [Green Version]
  46. Ali, A.; Shah, A.S.; Ahmad, A. Gain-of-function of mutant p53: Mutant p53 enhances cancer progression by inhibiting KLF17 expression in invasive breast carcinoma cells. Cancer Lett. 2014, 354, 87–96. [Google Scholar] [CrossRef]
  47. Xu, J.; Wang, J.; Hu, Y.; Qian, J.; Xu, B.; Chen, H.; Zou, W.; Fang, J.Y. Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity. Cell Death Dis. 2014, 5, e1108. [Google Scholar] [CrossRef] [Green Version]
  48. Karsy, M.; Arslan, E.; Moy, F. Current Progress on Understanding MicroRNAs in Glioblastoma Multiforme. Genes Cancer 2012, 3, 3–15. [Google Scholar] [CrossRef]
  49. Alexandrova, E.M.; Yallowitz, A.R.; Li, D.; Xu, S.; Schulz, R.; Proia, D.A.; Lozano, G.; Dobbelstein, M.; Moll, U.M. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature 2015, 523, 352–356. [Google Scholar] [CrossRef] [Green Version]
  50. Kollareddy, M.; Dimitrova, E.; Vallabhaneni, K.C.; Chan, A.; Le, T.; Chauhan, K.M.; Carrero, Z.I.; Ramakrishnan, G.; Watabe, K.; Haupt, Y.; et al. Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities. Nat. Commun. 2015, 6, 7389. [Google Scholar] [CrossRef] [Green Version]
  51. Wang, H.; Bao, W.; Jiang, F.; Che, Q.; Chen, Z.; Wang, F.; Tong, H.; Dai, C.; He, X.; Liao, Y.; et al. Mutant p53 (p53-R248Q) functions as an oncogene in promoting endometrial cancer by up-regulating REGgamma. Cancer Lett. 2015, 360, 269–279. [Google Scholar] [CrossRef] [PubMed]
  52. Ali, A.; Wang, Z.; Fu, J.; Ji, L.; Liu, J.; Li, L.; Wang, H.; Chen, J.; Caulin, C.; Myers, J.N.; et al. Differential regulation of the REGgamma-proteasome pathway by p53/TGF-beta signalling and mutant p53 in cancer cells. Nat. Commun. 2013, 4, 2667. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Kalo, E.; Kogan-Sakin, I.; Solomon, H.; Bar-Nathan, E.; Shay, M.; Shetzer, Y.; Dekel, E.; Goldfinger, N.; Buganim, Y.; Stambolsky, P.; et al. Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species. J. Cell Sci. 2012, 125, 5578–5586. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Liu, K.; Ling, S.; Lin, W.C. TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73. Mol. Cell Biol. 2011, 31, 4464–4481. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Nguyen, C.H.; Lang, B.J.; Chai, R.C.; Vieusseux, J.L.; Kouspou, M.M.; Price, J.T. Heat-shock factor 1 both positively and negatively affects cellular clonogenic growth depending on p53 status. Biochem. J. 2013, 452, 321–329. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Yan, W.; Chen, X. Identification of GRO1 as a critical determinant for mutant p53 gain of function. J. Biol. Chem. 2009, 284, 12178–12187. [Google Scholar] [CrossRef] [Green Version]
  57. Yeudall, W.A.; Vaughan, C.A.; Miyazaki, H.; Ramamoorthy, M.; Choi, M.Y.; Chapman, C.G.; Wang, H.; Black, E.; Bulysheva, A.A.; Deb, S.P.; et al. Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis 2012, 33, 442–451. [Google Scholar] [CrossRef]
  58. Dong, P.; Karaayvaz, M.; Jia, N.; Kaneuchi, M.; Hamada, J.; Watari, H.; Sudo, S.; Ju, J.; Sakuragi, N. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 2013, 32, 3286–3295. [Google Scholar] [CrossRef] [Green Version]
  59. Subramanian, M.; Francis, P.; Bilke, S.; Li, X.L.; Hara, T.; Lu, X.; Jones, M.F.; Walker, R.L.; Zhu, Y.; Pineda, M.; et al. A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis. Oncogene 2015, 34, 1094–1104. [Google Scholar] [CrossRef] [Green Version]
  60. Muller, P.A.; Caswell, P.T.; Doyle, B.; Iwanicki, M.P.; Tan, E.H.; Karim, S.; Lukashchuk, N.; Gillespie, D.A.; Ludwig, R.L.; Gosselin, P.; et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009, 139, 1327–1341. [Google Scholar] [CrossRef]
  61. Muller, P.A.; Trinidad, A.G.; Caswell, P.T.; Norman, J.C.; Vousden, K.H. Mutant p53 regulates Dicer through p63-dependent and -independent mechanisms to promote an invasive phenotype. J. Biol. Chem. 2014, 289, 122–132. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  62. Muller, P.A.; Trinidad, A.G.; Timpson, P.; Morton, J.P.; Zanivan, S.; van den Berghe, P.V.; Nixon, C.; Karim, S.A.; Caswell, P.T.; Noll, J.E.; et al. Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene 2013, 32, 1252–1265. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Weissmueller, S.; Manchado, E.; Saborowski, M.; Morris, J.P.t.; Wagenblast, E.; Davis, C.A.; Moon, S.H.; Pfister, N.T.; Tschaharganeh, D.F.; Kitzing, T.; et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling. Cell 2014, 157, 382–394. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Freed-Pastor, W.A.; Mizuno, H.; Zhao, X.; Langerod, A.; Moon, S.H.; Rodriguez-Barrueco, R.; Barsotti, A.; Chicas, A.; Li, W.; Polotskaia, A.; et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012, 148, 244–258. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Arjonen, A.; Kaukonen, R.; Mattila, E.; Rouhi, P.; Hognas, G.; Sihto, H.; Miller, B.W.; Morton, J.P.; Bucher, E.; Taimen, P.; et al. Mutant p53-associated myosin-X upregulation promotes breast cancer invasion and metastasis. J. Clin. Invest. 2014, 124, 1069–1082. [Google Scholar] [CrossRef] [Green Version]
  66. Nakayama, M.; Oshima, M. Mutant p53 in colon cancer. J. Mol. Cell Biol. 2019, 11, 267–276. [Google Scholar] [CrossRef] [Green Version]
  67. Nakayama, M.; Sakai, E.; Echizen, K.; Yamada, Y.; Oshima, H.; Han, T.S.; Ohki, R.; Fujii, S.; Ochiai, A.; Robine, S.; et al. Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation. Oncogene 2017, 36, 5885–5896. [Google Scholar] [CrossRef] [Green Version]
  68. Khromova, N.V.; Kopnin, P.B.; Stepanova, E.V.; Agapova, L.S.; Kopnin, B.P. p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway. Cancer Lett. 2009, 276, 143–151. [Google Scholar] [CrossRef]
  69. Joshi, H.; Bhanot, G.; Borresen-Dale, A.L.; Kristensen, V. Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway. Br. J. Cancer 2012, 107, 1722–1728. [Google Scholar] [CrossRef]
  70. Montero, E.; Abreu, C.; Tonino, P. Relationship between VEGF and p53 expression and tumor cell proliferation in human gastrointestinal carcinomas. J. Cancer Res. Clin. Oncol. 2008, 134, 193–201. [Google Scholar] [CrossRef]
  71. Fontemaggi, G.; Dell’Orso, S.; Trisciuoglio, D.; Shay, T.; Melucci, E.; Fazi, F.; Terrenato, I.; Mottolese, M.; Muti, P.; Domany, E.; et al. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat. Struct. Mol. Biol. 2009, 16, 1086–1093. [Google Scholar] [CrossRef] [PubMed]
  72. Pfister, N.T.; Fomin, V.; Regunath, K.; Zhou, J.Y.; Zhou, W.; Silwal-Pandit, L.; Freed-Pastor, W.A.; Laptenko, O.; Neo, S.P.; Bargonetti, J.; et al. Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes Dev. 2015, 29, 1298–1315. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  73. Zhu, J.; Sammons, M.A.; Donahue, G.; Dou, Z.; Vedadi, M.; Getlik, M.; Barsyte-Lovejoy, D.; Al-awar, R.; Katona, B.W.; Shilatifard, A.; et al. Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature 2015, 525, 206–211. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Rahnamoun, H.; Lu, H.; Duttke, S.H.; Benner, C.; Glass, C.K.; Lauberth, S.M. Mutant p53 shapes the enhancer landscape of cancer cells in response to chronic immune signaling. Nat. Commun. 2017, 8, 754. [Google Scholar] [CrossRef] [PubMed]
  75. Zhang, C.; Su, Z.Y.; Wang, L.; Shu, L.; Yang, Y.; Guo, Y.; Pung, D.; Bountra, C.; Kong, A.N. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1. Biochem. Pharm. 2016, 117, 35–45. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  76. Zhang, L.; Tong, Y.; Zhang, X.; Pan, M.; Chen, S. Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth. Drug Des. Devel. 2015, 9, 5851–5862. [Google Scholar]
  77. Zhang, Y.; Tian, S.; Xiong, J.; Zhou, Y.; Song, H.; Liu, C. JQ-1 Inhibits Colon Cancer Proliferation via Suppressing Wnt/beta-Catenin Signaling and miR-21. Chem. Res. Toxicol. 2018, 31, 302–307. [Google Scholar] [CrossRef] [Green Version]
  78. Vaughan, C.A.; Frum, R.; Pearsall, I.; Singh, S.; Windle, B.; Yeudall, A.; Deb, S.P.; Deb, S. Allele specific gain-of-function activity of p53 mutants in lung cancer cells. Biochem. Biophys. Res. Commun. 2012, 428, 6–10. [Google Scholar] [CrossRef] [Green Version]
  79. Gurtner, A.; Starace, G.; Norelli, G.; Piaggio, G.; Sacchi, A.; Bossi, G. Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function. J. Biol. Chem. 2010, 285, 14160–14169. [Google Scholar] [CrossRef] [Green Version]
  80. Lin, C.; Liang, Y.; Zhu, H.; Zhang, J.; Zhong, X. R280T mutation of p53 gene promotes proliferation of human glioma cells through GSK-3beta/PTEN pathway. Neurosci. Lett. 2012, 529, 60–65. [Google Scholar] [CrossRef]
  81. Girardini, J.E.; Napoli, M.; Piazza, S.; Rustighi, A.; Marotta, C.; Radaelli, E.; Capaci, V.; Jordan, L.; Quinlan, P.; Thompson, A.; et al. A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 2011, 20, 79–91. [Google Scholar] [CrossRef] [PubMed]
  82. Martins, C.P.; Brown-Swigart, L.; Evan, G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006, 127, 1323–1334. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  83. Ventura, A.; Kirsch, D.G.; McLaughlin, M.E.; Tuveson, D.A.; Grimm, J.; Lintault, L.; Newman, J.; Reczek, E.E.; Weissleder, R.; Jacks, T. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445, 661–665. [Google Scholar] [CrossRef] [PubMed]
  84. Xue, W.; Zender, L.; Miething, C.; Dickins, R.A.; Hernando, E.; Krizhanovsky, V.; Cordon-Cardo, C.; Lowe, S.W. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445, 656–660. [Google Scholar] [CrossRef] [Green Version]
  85. Wischhusen, J.; Naumann, U.; Ohgaki, H.; Rastinejad, F.; Weller, M. CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 2003, 22, 8233–8245. [Google Scholar] [CrossRef] [Green Version]
  86. Foster, B.A.; Coffey, H.A.; Morin, M.J.; Rastinejad, F. Pharmacological rescue of mutant p53 conformation and function. Science 1999, 286, 2507–2510. [Google Scholar] [CrossRef] [Green Version]
  87. Rippin, T.M.; Bykov, V.J.; Freund, S.M.; Selivanova, G.; Wiman, K.G.; Fersht, A.R. Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 2002, 21, 2119–2129. [Google Scholar] [CrossRef] [Green Version]
  88. Tang, X.; Zhu, Y.; Han, L.; Kim, A.L.; Kopelovich, L.; Bickers, D.R.; Athar, M. CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J. Clin. Invest. 2007, 117, 3753–3764. [Google Scholar] [CrossRef] [Green Version]
  89. Bykov, V.J.; Issaeva, N.; Shilov, A.; Hultcrantz, M.; Pugacheva, E.; Chumakov, P.; Bergman, J.; Wiman, K.G.; Selivanova, G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 2002, 8, 282–288. [Google Scholar] [CrossRef]
  90. Bykov, V.J.; Zache, N.; Stridh, H.; Westman, J.; Bergman, J.; Selivanova, G.; Wiman, K.G. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 2005, 24, 3484–3491. [Google Scholar] [CrossRef] [Green Version]
  91. Duffy, M.J.; Synnott, N.C.; McGowan, P.M.; Crown, J.; O’Connor, D.; Gallagher, W.M. p53 as a target for the treatment of cancer. Cancer Treat. Rev. 2014, 40, 1153–1160. [Google Scholar] [CrossRef] [PubMed]
  92. Zandi, R.; Selivanova, G.; Christensen, C.L.; Gerds, T.A.; Willumsen, B.M.; Poulsen, H.S. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Clin. Cancer Res. 2011, 17, 2830–2841. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  93. Lambert, J.M.; Gorzov, P.; Veprintsev, D.B.; Soderqvist, M.; Segerback, D.; Bergman, J.; Fersht, A.R.; Hainaut, P.; Wiman, K.G.; Bykov, V.J. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 2009, 15, 376–388. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  94. p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy with or without APR-246. 2014. Available online: https://clinicaltrials.gov/ct2/show/NCT02098343 (accessed on 27 November 2019).
  95. A Study of APR-246 in Oesophageal Cancer (APROC). 2016. Available online: https://clinicaltrials.gov/ct2/show/NCT02999893 (accessed on 27 November 2019).
  96. Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms. 2017. Available online: https://clinicaltrials.gov/ct2/show/NCT03072043 (accessed on 27 November 2019).
  97. Bykov, V.J.N.; Eriksson, S.E.; Bianchi, J.; Wiman, K.G. Targeting mutant p53 for efficient cancer therapy. Nat. Rev. Cancer 2018, 18, 89–102. [Google Scholar] [CrossRef] [PubMed]
  98. Bykov, V.J.; Issaeva, N.; Zache, N.; Shilov, A.; Hultcrantz, M.; Bergman, J.; Selivanova, G.; Wiman, K.G. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J. Biol. Chem. 2005, 280, 30384–30391. [Google Scholar] [CrossRef] [Green Version]
  99. Zache, N.; Lambert, J.M.R.; Rokaeus, N.; Shen, J.; Hainaut, P.; Bergman, J.; Wiman, K.G.; Bykov, V.J.N. Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol. Oncol. 2017, 11, 595. [Google Scholar] [CrossRef] [Green Version]
  100. Punganuru, S.R.; Madala, H.R.; Venugopal, S.N.; Samala, R.; Mikelis, C.; Srivenugopal, K.S. Design and synthesis of a C7-aryl piperlongumine derivative with potent antimicrotubule and mutant p53-reactivating properties. Eur. J. Med. Chem. 2016, 107, 233–244. [Google Scholar] [CrossRef]
  101. Bauer, M.R.; Joerger, A.C.; Fersht, A.R. 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells. Proc. Natl. Acad. Sci. USA 2016, 113, E5271–E5280. [Google Scholar] [CrossRef] [Green Version]
  102. Kaar, J.L.; Basse, N.; Joerger, A.C.; Stephens, E.; Rutherford, T.J.; Fersht, A.R. Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding. Protein Sci. A Publ. Protein Soc. 2010, 19, 2267–2278. [Google Scholar] [CrossRef] [Green Version]
  103. Puca, R.; Nardinocchi, L.; Porru, M.; Simon, A.J.; Rechavi, G.; Leonetti, C.; Givol, D.; D’Orazi, G. Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle 2011, 10, 1679–1689. [Google Scholar] [CrossRef]
  104. Yu, X.; Vazquez, A.; Levine, A.J.; Carpizo, D.R. Allele-specific p53 mutant reactivation. Cancer Cell 2012, 21, 614–625. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  105. Salim, K.Y.; Maleki Vareki, S.; Danter, W.R.; Koropatnick, J. COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo. Oncotarget 2016, 7, 41363–41379. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  106. Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101). 2015. Available online: https://clinicaltrials.gov/ct2/show/NCT02433626 (accessed on 27 November 2019).
  107. Tal, P.; Eizenberger, S.; Cohen, E.; Goldfinger, N.; Pietrokovski, S.; Oren, M.; Rotter, V. Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides. Oncotarget 2016, 7, 11817–11837. [Google Scholar] [CrossRef] [Green Version]
  108. Soragni, A.; Janzen, D.M.; Johnson, L.M.; Lindgren, A.G.; Thai-Quynh Nguyen, A.; Tiourin, E.; Soriaga, A.B.; Lu, J.; Jiang, L.; Faull, K.F.; et al. A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas. Cancer Cell 2016, 29, 90–103. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  109. Boeckler, F.M.; Joerger, A.C.; Jaggi, G.; Rutherford, T.J.; Veprintsev, D.B.; Fersht, A.R. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc. Natl. Acad. Sci. USA 2008, 105, 10360–10365. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  110. Liu, X.; Wilcken, R.; Joerger, A.C.; Chuckowree, I.S.; Amin, J.; Spencer, J.; Fersht, A.R. Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res. 2013, 41, 6034–6044. [Google Scholar] [CrossRef]
  111. Weinmann, L.; Wischhusen, J.; Demma, M.J.; Naumann, U.; Roth, P.; Dasmahapatra, B.; Weller, M. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 2008, 15, 718–729. [Google Scholar] [CrossRef]
  112. Demma, M.; Maxwell, E.; Ramos, R.; Liang, L.; Li, C.; Hesk, D.; Rossman, R.; Mallams, A.; Doll, R.; Liu, M.; et al. SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53. J. Biol. Chem. 2010, 285, 10198–10212. [Google Scholar] [CrossRef] [Green Version]
  113. Hiraki, M.; Hwang, S.Y.; Cao, S.; Ramadhar, T.R.; Byun, S.; Yoon, K.W.; Lee, J.H.; Chu, K.; Gurkar, A.U.; Kolev, V.; et al. Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis. Chem. Biol. 2015, 22, 1206–1216. [Google Scholar] [CrossRef] [Green Version]
  114. Kravchenko, J.E.; Ilyinskaya, G.V.; Komarov, P.G.; Agapova, L.S.; Kochetkov, D.V.; Strom, E.; Frolova, E.I.; Kovriga, I.; Gudkov, A.V.; Feinstein, E.; et al. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc. Natl. Acad. Sci. USA 2008, 105, 6302–6307. [Google Scholar] [CrossRef] [Green Version]
  115. Schulz-Heddergott, R.; Stark, N.; Edmunds, S.J.; Li, J.; Conradi, L.C.; Bohnenberger, H.; Ceteci, F.; Greten, F.R.; Dobbelstein, M.; Moll, U.M. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion. Cancer Cell 2018, 34, 298–314. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  116. Li, D.; Marchenko, N.D.; Schulz, R.; Fischer, V.; Velasco-Hernandez, T.; Talos, F.; Moll, U.M. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol. Cancer Res. 2011, 9, 577–588. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  117. Li, D.; Marchenko, N.D.; Moll, U.M. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ. 2011, 18, 1904–1913. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  118. Yan, W.; Zhang, Y.; Zhang, J.; Liu, S.; Cho, S.J.; Chen, X. Mutant p53 protein is targeted by arsenic for degradation and plays a role in arsenic-mediated growth suppression. J. Biol. Chem. 2011, 286, 17478–17486. [Google Scholar] [CrossRef] [Green Version]
  119. Yan, W.; Jung, Y.S.; Zhang, Y.; Chen, X. Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase. PLoS ONE 2014, 9, e103497. [Google Scholar] [CrossRef]
  120. Parrales, A.; Iwakuma, T. Targeting Oncogenic Mutant p53 for Cancer Therapy. Front. Oncol. 2015, 5, 288. [Google Scholar] [CrossRef] [Green Version]
  121. Wang, J.; Zhao, Q.; Qi, Q.; Gu, H.Y.; Rong, J.J.; Mu, R.; Zou, M.J.; Tao, L.; You, Q.D.; Guo, Q.L. Gambogic acid-induced degradation of mutant p53 is mediated by proteasome and related to CHIP. J. Cell. Biochem. 2011, 112, 509–519. [Google Scholar] [CrossRef]
  122. Vakifahmetoglu-Norberg, H.; Kim, M.; Xia, H.G.; Iwanicki, M.P.; Ofengeim, D.; Coloff, J.L.; Pan, L.; Ince, T.A.; Kroemer, G.; Brugge, J.S.; et al. Chaperone-mediated autophagy degrades mutant p53. Genes Dev. 2013, 27, 1718–1730. [Google Scholar] [CrossRef] [Green Version]
  123. Rifai, K.; Judes, G.; Idrissou, M.; Daures, M.; Bignon, Y.J.; Penault-Llorca, F.; Bernard-Gallon, D. Dual SIRT1 expression patterns strongly suggests its bivalent role in human breast cancer. Oncotarget 2017, 8, 110922–110930. [Google Scholar] [CrossRef] [Green Version]
  124. Zhang, S.; Zhou, L.; Hong, B.; van den Heuvel, A.P.; Prabhu, V.V.; Warfel, N.A.; Kline, C.L.; Dicker, D.T.; Kopelovich, L.; El-Deiry, W.S. Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53. Cancer Res. 2015, 75, 3842–3852. [Google Scholar] [CrossRef] [Green Version]
  125. Paranjpe, A.; Srivenugopal, K.S. Degradation of NF-kappaB, p53 and other regulatory redox-sensitive proteins by thiol-conjugating and -nitrosylating drugs in human tumor cells. Carcinogenesis 2013, 34, 990–1000. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  126. Wang, Q.; Fan, S.; Eastman, A.; Worland, P.J.; Sausville, E.A.; O’Connor, P.M. UCN-01: A potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst. 1996, 88, 956–965. [Google Scholar] [CrossRef] [PubMed]
  127. Sur, S.; Pagliarini, R.; Bunz, F.; Rago, C.; Diaz, L.A., Jr.; Kinzler, K.W.; Vogelstein, B.; Papadopoulos, N. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc. Natl. Acad. Sci. USA 2009, 106, 3964–3969. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  128. Wang, Y.; Li, J.; Booher, R.N.; Kraker, A.; Lawrence, T.; Leopold, W.R.; Sun, Y. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res. 2001, 61, 8211–8217. [Google Scholar]
  129. Sorrentino, G.; Ruggeri, N.; Specchia, V.; Cordenonsi, M.; Mano, M.; Dupont, S.; Manfrin, A.; Ingallina, E.; Sommaggio, R.; Piazza, S.; et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat. Cell Biol. 2014, 16, 357–366. [Google Scholar] [CrossRef]
Ijms 20 05999 g001 550
Figure 1. The consequences of somatic TP53 mutations in tumorigenesis. The outcomes of p53 mutants are loss of wild type function and gain of new function. The LOH (loss of heterozygosity) and DNE (dominant-negative effect) are the two major main mechanisms to abrogate the tumor suppressor function of wild type p53. In some cancer cases with TP53 mutations, the GOF (gain-of-function) of p53 mutants are empowered with kinds of oncogenic potentials, which promote cancer initiation and progression.
Figure 1. The consequences of somatic TP53 mutations in tumorigenesis. The outcomes of p53 mutants are loss of wild type function and gain of new function. The LOH (loss of heterozygosity) and DNE (dominant-negative effect) are the two major main mechanisms to abrogate the tumor suppressor function of wild type p53. In some cancer cases with TP53 mutations, the GOF (gain-of-function) of p53 mutants are empowered with kinds of oncogenic potentials, which promote cancer initiation and progression.
Ijms 20 05999 g001
Ijms 20 05999 g002 550
Figure 2. The multiple mechanisms of p53 mutants with GOF in CRC and other solid tumors. Upper, p53 mutants bind to TF (transcription factor) and activates target gene expression, such as c-Myc and Bcl-XL. Middle, p53 mutants bind to TFs (p63 and p73) and subvert their binding affinities to targeted promoters, which suppresses target gene expression. Lower, p53 mutants bind to and activate chromatin modifying enzymes to remodel the chromatin and promote target gene transactivation.
Figure 2. The multiple mechanisms of p53 mutants with GOF in CRC and other solid tumors. Upper, p53 mutants bind to TF (transcription factor) and activates target gene expression, such as c-Myc and Bcl-XL. Middle, p53 mutants bind to TFs (p63 and p73) and subvert their binding affinities to targeted promoters, which suppresses target gene expression. Lower, p53 mutants bind to and activate chromatin modifying enzymes to remodel the chromatin and promote target gene transactivation.
Ijms 20 05999 g002
Ijms 20 05999 g003 550
Figure 3. Strategies targeting p53 mutants with GOF. The strategies have been extensively undertaken to develop small molecular compounds that specifically target p53 mutants. The detailed mechanisms include restoring p53 wild type function, depleting p53 mutants, inducing synthetic lethality of p53 mutants and inhibiting the oncogenic downstream targets of p53 mutants. The cysteine-binding compounds, Zn2+-chelating compounds, peptides and other types’ compounds are employed to reactivate p53 wild type function, which are listed in the frame on the left. The compounds inducing p53 mutant depletion are listed in the right frame. The upper frame demonstrates the compounds which could induce synthetic lethality, including UCN01, BI-2536 and PD0166285. Statins and Integrin inhibitor have been reported to successfully inhibit p53 mutants’ downstream targets.
Figure 3. Strategies targeting p53 mutants with GOF. The strategies have been extensively undertaken to develop small molecular compounds that specifically target p53 mutants. The detailed mechanisms include restoring p53 wild type function, depleting p53 mutants, inducing synthetic lethality of p53 mutants and inhibiting the oncogenic downstream targets of p53 mutants. The cysteine-binding compounds, Zn2+-chelating compounds, peptides and other types’ compounds are employed to reactivate p53 wild type function, which are listed in the frame on the left. The compounds inducing p53 mutant depletion are listed in the right frame. The upper frame demonstrates the compounds which could induce synthetic lethality, including UCN01, BI-2536 and PD0166285. Statins and Integrin inhibitor have been reported to successfully inhibit p53 mutants’ downstream targets.
Ijms 20 05999 g003
Table
Table 1. The promoting roles of p53 mutants with GOF in solid tumor cells.
Table 1. The promoting roles of p53 mutants with GOF in solid tumor cells.
Mutation TypeCell LinesDownstream EffectorsRefs
Promoting cell proliferation
R273HU373/SNB19c-Myc/Bcl-XL[40]
R280K/R282WMDA-MB-231/MDA-MB-1386KLF17[46]
R273HH1299miR-27a/EGFR[47]
R273H/R175H/D281GH1299Axl[48]
R273C/R267PH1048/H1437
R238Q/R172H-HSP90/HDAC6[49]
R249S/R273L/R280KBT549/HCC38/MDAMB231EST2/NMGs[50]
R249S/R175HMCF10a/H1299
R248QHEC-1BREG-γ[51]
R175HH1299/UMSCC-1REG-γ[52]
R280K/R282W/R273HMDA-MB-231/MDA-MB-1386
P278S/R267PABC1/H1437Axl[78]
R175H/R273HH1299TopBP1[54]
R273C/R248Q/R175HC33A/OVCAR-3/SKBr3
R175H/R273H/R280KSKBR3/HT29/MDA-MB468/MDA-MB231MAP2K3[79]
R280TSWO-38GSK-3β/PTEN[80]
R280K/R273HMDA-MB-231/MDA-468SREBPs[64]
Increasing colony formation ability
R273HU373/SNB19c-Myc/Bcl-XL[40]
R273HH1299NRF2[53]
R175H/R273HH1299TopBP1[54]
R273C/R248Q/R175HC33A/OVCAR-3/SKBr3
R273HMCF10aHSF1[55]
R273HH1299miR-27a/EGFR[47]
R175HHCT116-/-GRO1[56]
R273H/P309SSW480
R248WMIA-PaCa-2
Increasing cell invasion and migration
R273HU373/SNB19c-Myc/Bcl-XL[40]
R280K/R282WMDA-MB-231/MDA-MB-1386KLF17[46]
R249S/R273L/R280KBT549/HCC38/MDAMB231EST2/NMGs[50]
R249S/R175HMCF10a/H1299
R248QHEC-1BREG-γ[51]
R175H/R273HMCF10a/H1299RCP/integrin/EGFR[60]
R273HH1299TAp63/Dicer[61]
R280K/R273HMDA-MB-231/HT29/A431
R175H/R273HH1299TAp63/Met[62]
R175HH1299TAp63/Sharp 1/Cyclin G2[41]
R175HH1299Smad3[42]
R175HH1299let-7i/E2F5/LIN28B/MYC[59]
R248W/R220C/H242R/H155PMiapaca2/BXPC3/CFPAC/A2.1p73/NF-Y/PDGFR-beta[63]
R273H/R280KSW620/H1975/MDA-MB-231
R280K/R273HMDA-MB-231/MDA-468SREBPs[64]
R280KMDA-MB-231Myo10[65]
R175H/R273H/C135YHEC-50miR-130b/ZEB1[58]
R273HU373/SNB19c-Myc/Bcl-XL[40]
R280KMDA-MB-231KLF17[46]
R282WMDA-MB-1386
R273H/R175H/D281GH1299Axl[48]
R273C/R267PH1048/H1437
R175HH1299TAp63/Sharp 1/Cyclin G2[41]
R175HH1299let-7i/E2F5/LIN28B/MYC[59]
R175H/R273H/D281GH1299CXCL5/CXCL8/CXCL12[57]
R280KMDA-MB-231Pin1[81]
Inducing angiogenesis
R175H/R273H/R248WHCT116-/-HIF1/VEGF-A[68]
R175H/R273HH1299ID4/IL8/GRO-a[71]
R280KMDA-MB-231
Chromatin remodeling
R248QHCC70MLL1/MLL2/MOZ[73]
R249SBT-549
R273HMDA-MB-468
R273HSW480MMP9/CCL2/CYP24A1/CPA4[74]
R273HMDA-468VEGFR2/SWI/SNF[72]
Table
Table 2. The list of compounds targeting p53 mutants.
Table 2. The list of compounds targeting p53 mutants.
Reactivating the Wild Type p53 Function
Compounds
(Small Molecules)		MechanismsClinical Trial (Cancers)Refs.
Cysteine-binding compounds
CP-31398binds to the cysteine residues [85,86,87,88]
PRIMA-1converts to methylene quinuclidinone [89,90,91,92]
APR-246converts to methylene quinuclidinonephase Ib/II (lymphoma, ovarian, esophageal)[90,91,92,93,94]
MIRA-1prevents unfolding of wild-type and mutant p53 [98]
STIMA-1prevents unfolding of wild-type and mutant p53 [99]
KSS-9prevents unfolding of wild-type and mutant p53 [100]
PK11007binds p53 by nucleophilic aromatic substitution [101]
3-Benzoylacrylic acidbinds p53 by Michael addition [102]
Zn2+-chelating compounds
ZMC-1Zn2+ chelator [104]
COTI-2Zn2+ chelatorphase I (gynecological, head and neck cancer)[105]
Peptides
pCAPspromote refolding [107]
Reacp53blocks aggregation [108]
Other types of compounds
PK083restores wild-type conformation [109]
PK7088restores wild-type conformation [105]
P53R3restores DNA-binding ability [106]
SCH529074restores DNA-binding ability [112]
Chetominpromotes refolding [113]
RETRAdisrupts mutant p53–p73 complexes [114]
Depleting the GOF of p53 mutants
17AAGHsp90 inhibitors [116]
GanetespibHsp90 inhibitorsphase III (lung cancer)[49]
SAHAHDAC inhibitors [117]
Arsenic compoundsincreases transcripts of Pirh2,and [118]
induces degradation of mutant p53 [119]
Gambogic acidinhibits the mutant p53-Hsp90 complex [121]
Spautin-1induces mutant p53 degradation [122]
YK-3-237activates SIRT1 and deacetylate lysine 382 [123]
NSC59984induces MDM2-mediated mutant p53 degradation [124]
Disulfiraminduces p53 degradation [125]
Inducing synthetic lethality
UCN01protein kinase C inhibitor [126]
BI-2536polo-like kinase 1 inhibitor [127]
PD0166285Wee1 kinase inhibitor [128]
Blocking the oncogenic downstreams of p53 mutants
StatinsHMG-CoA reductase inhibitor [64]
inhibits YAP/TAZ activation [129]

Share and Cite

MDPI and ACS Style

Li, H.; Zhang, J.; Tong, J.H.M.; Chan, A.W.H.; Yu, J.; Kang, W.; To, K.F. Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors. Int. J. Mol. Sci. 2019, 20, 5999. https://doi.org/10.3390/ijms20235999

AMA Style

Li H, Zhang J, Tong JHM, Chan AWH, Yu J, Kang W, To KF. Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors. International Journal of Molecular Sciences. 2019; 20(23):5999. https://doi.org/10.3390/ijms20235999

Chicago/Turabian Style

Li, Hui, Jinglin Zhang, Joanna Hung Man Tong, Anthony Wing Hung Chan, Jun Yu, Wei Kang, and Ka Fai To. 2019. "Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors" International Journal of Molecular Sciences 20, no. 23: 5999. https://doi.org/10.3390/ijms20235999

APA Style

Li, H., Zhang, J., Tong, J. H. M., Chan, A. W. H., Yu, J., Kang, W., & To, K. F. (2019). Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors. International Journal of Molecular Sciences, 20(23), 5999. https://doi.org/10.3390/ijms20235999

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop